[go: up one dir, main page]

IN2014DN06166A - - Google Patents

Info

Publication number
IN2014DN06166A
IN2014DN06166A IN6166DEN2014A IN2014DN06166A IN 2014DN06166 A IN2014DN06166 A IN 2014DN06166A IN 6166DEN2014 A IN6166DEN2014 A IN 6166DEN2014A IN 2014DN06166 A IN2014DN06166 A IN 2014DN06166A
Authority
IN
India
Prior art keywords
salts
compositions
methods
tricyclic compounds
fused tricyclic
Prior art date
Application number
Other languages
English (en)
Inventor
Changyou Zhou
Shaohui Wang
Guoliang Zhang
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of IN2014DN06166A publication Critical patent/IN2014DN06166A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/02—Ergot alkaloids of the cyclic peptide type

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IN6166DEN2014 2011-12-31 2011-12-31 IN2014DN06166A (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2011/085146 WO2013097224A1 (en) 2011-12-31 2011-12-31 Fused tricyclic compounds as raf kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2014DN06166A true IN2014DN06166A (lt) 2015-08-21

Family

ID=48696279

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6166DEN2014 IN2014DN06166A (lt) 2011-12-31 2011-12-31

Country Status (29)

Country Link
US (3) US9273046B2 (lt)
EP (2) EP2797888B1 (lt)
JP (1) JP5868521B2 (lt)
KR (1) KR101713391B1 (lt)
CN (1) CN103596926B (lt)
AU (1) AU2011384857B2 (lt)
BR (1) BR112014013108B1 (lt)
CA (1) CA2856347C (lt)
CY (1) CY1118226T1 (lt)
DK (1) DK2797888T3 (lt)
EA (1) EA025597B1 (lt)
ES (1) ES2588775T3 (lt)
HK (2) HK1192232A1 (lt)
HR (1) HRP20160641T1 (lt)
HU (1) HUE029656T2 (lt)
IL (1) IL233364A (lt)
IN (1) IN2014DN06166A (lt)
LT (1) LT2797888T (lt)
ME (1) ME02529B (lt)
MX (1) MX352617B (lt)
NZ (1) NZ624068A (lt)
PL (1) PL2797888T3 (lt)
PT (1) PT2797888T (lt)
RS (1) RS55196B1 (lt)
SG (1) SG11201401725SA (lt)
SI (1) SI2797888T1 (lt)
SM (1) SMT201600302B (lt)
WO (1) WO2013097224A1 (lt)
ZA (1) ZA201405555B (lt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014013108B1 (pt) 2011-12-31 2020-11-24 Beigene, Ltd. compostos, composição farmacêutica, uso do composto e método
KR102272606B1 (ko) 2013-06-28 2021-07-05 베이진 엘티디 Raf 키나아제 및/또는 raf 키나아제 이량체 저해제로서 융합 트리시클릭 우레아 화합물
WO2014206344A1 (en) 2013-06-28 2014-12-31 Beigene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors
WO2015089809A1 (en) * 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
WO2015176267A1 (en) * 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
GB201416186D0 (en) * 2014-09-12 2014-10-29 Redx Pharma Ltd Compounds
EP4119559A1 (en) * 2015-04-15 2023-01-18 BeiGene, Ltd. Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
JP6175519B2 (ja) * 2016-01-04 2017-08-09 ベイジーン リミテッド Ｒａｆキナーゼ阻害剤としての縮合三環式化合物
JP6993056B2 (ja) * 2016-07-05 2022-02-15 ベイジーン リミテッド 癌治療のためのｐｄ－１アンタゴニスト及びｒａｆ阻害剤の組合せ
HUE064609T2 (hu) 2016-12-01 2024-04-28 Arvinas Operations Inc Tetrahidronaftalin és tetrahidroizokinolin származékok mint ösztrogénreceptor-lebontó anyagok
US10723717B2 (en) * 2016-12-23 2020-07-28 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
WO2020055760A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
CN111184693B (zh) * 2019-05-29 2023-07-21 百济神州(苏州)生物科技有限公司 一种raf激酶抑制剂制剂及其制备方法
US12208095B2 (en) 2019-08-26 2025-01-28 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
TW202136240A (zh) 2019-12-19 2021-10-01 美商亞文納營運公司 用於靶向降解雄激素受體之化合物及方法
CA3187514A1 (en) 2020-07-28 2022-02-03 Andrew BELFIELD Fused bicyclic raf inhibitors and methods for use thereof
JP2023539663A (ja) 2020-08-28 2023-09-15 アルビナス・オペレーションズ・インコーポレイテッド 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法
RS20230288A1 (sr) 2020-09-14 2023-06-30 Arvinas Operations Inc Kristalni i amorfni oblici jedinjenja za ciljanu degradaciju receptora estrogena
EP4404935A1 (en) * 2021-09-21 2024-07-31 Merck Sharp & Dohme LLC Allosteric modulators of nicotinic acetylcholine receptors
WO2023209611A1 (en) 2022-04-26 2023-11-02 Beigene Switzerland Gmbh Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib
WO2023212071A1 (en) * 2022-04-26 2023-11-02 Beigene Switzerland Gmbh Combination and the use thereof
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003245700A1 (en) 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
SI1696920T1 (sl) 2003-12-19 2015-02-27 Plexxikon Inc. Spojine in postopki za razvoj modulatorjev ret
EP1828186A1 (en) 2004-12-13 2007-09-05 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
JP2008525355A (ja) 2004-12-23 2008-07-17 エフ．ホフマン−ラ ロシュ アーゲー ベンズアミド誘導体、これらの製造及び医薬剤としての使用。
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
CA2608733A1 (en) 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
EP1902056A2 (en) 2005-05-20 2008-03-26 Array Biopharma, Inc. Raf inhibitor compounds and methods of use thereof
HUE027370T2 (en) 2005-06-22 2016-10-28 Plexxikon Inc Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors
EP1934228A2 (en) 2005-09-01 2008-06-25 Array Biopharma, Inc. Raf inhibitor compounds and methods of use thereof
ZA200804679B (en) * 2005-12-08 2010-02-24 Millenium Pharmaceuticals Inc Bicyclic compounds with kinase inhibitory activity
US7442808B2 (en) * 2006-05-15 2008-10-28 Merck & Co., Inc. Antidiabetic bicyclic compounds
KR20090052884A (ko) * 2006-08-23 2009-05-26 화이자 프로덕츠 인크. Ｇｓｋ-3 억제제로서의 피리미돈 화합물
WO2008028617A1 (en) 2006-09-06 2008-03-13 F. Hoffmann-La Roche Ag Heteroaryl derivatives as protein kinase inhibitors
EP2061761A1 (en) * 2006-09-07 2009-05-27 Millennium Pharmaceuticals, Inc. Phenethylamide derivatives with kinase inhibitory activity
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
JP2010526150A (ja) * 2007-05-04 2010-07-29 アイアールエム・リミテッド・ライアビリティ・カンパニー ｃ−ｋｉｔおよびＰＤＧＦＲキナーゼインヒビターとしての化合物および組成物
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
US20100197924A1 (en) 2008-12-22 2010-08-05 Millennium Pharmaceuticals, Inc. Preparation of aminotetralin compounds
BR112014013108B1 (pt) 2011-12-31 2020-11-24 Beigene, Ltd. compostos, composição farmacêutica, uso do composto e método
EP4119559A1 (en) 2015-04-15 2023-01-18 BeiGene, Ltd. Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore

Also Published As

Publication number Publication date
EA025597B1 (ru) 2017-01-30
EP2797888A1 (en) 2014-11-05
EP2797888B1 (en) 2016-06-08
HUE029656T2 (en) 2017-03-28
CA2856347C (en) 2017-05-30
EA201491305A1 (ru) 2015-04-30
IL233364A0 (en) 2014-08-31
DK2797888T3 (en) 2016-09-19
SG11201401725SA (en) 2014-09-26
US9273046B2 (en) 2016-03-01
ES2588775T3 (es) 2016-11-04
HRP20160641T1 (hr) 2016-09-23
HK1221222A1 (zh) 2017-05-26
EP3124472B1 (en) 2018-07-25
US20150045355A1 (en) 2015-02-12
ME02529B (me) 2017-02-20
AU2011384857A1 (en) 2014-05-29
IL233364A (en) 2017-06-29
US9895376B2 (en) 2018-02-20
US20160206621A1 (en) 2016-07-21
PL2797888T3 (pl) 2016-12-30
MX2014007829A (es) 2014-08-01
WO2013097224A1 (en) 2013-07-04
JP2015506353A (ja) 2015-03-02
NZ624068A (en) 2016-09-30
LT2797888T (lt) 2016-10-10
RS55196B1 (sr) 2017-01-31
CA2856347A1 (en) 2013-07-04
KR20140108541A (ko) 2014-09-11
SI2797888T1 (sl) 2017-01-31
CN103596926B (zh) 2015-11-25
HK1192232A1 (zh) 2014-08-15
CN103596926A (zh) 2014-02-19
KR101713391B1 (ko) 2017-03-07
ZA201405555B (en) 2015-10-28
EP3124472A1 (en) 2017-02-01
MX352617B (es) 2017-12-01
JP5868521B2 (ja) 2016-02-24
BR112014013108B1 (pt) 2020-11-24
CY1118226T1 (el) 2017-06-28
EP2797888A4 (en) 2015-09-02
US20190000857A1 (en) 2019-01-03
AU2011384857B2 (en) 2016-03-03
BR112014013108A2 (pt) 2017-06-13
US10576087B2 (en) 2020-03-03
PT2797888T (pt) 2016-09-09
SMT201600302B (it) 2016-11-10

Similar Documents

Publication Publication Date Title
IN2014DN06166A (lt)
IN2014CN02639A (lt)
MX2014007840A (es) Dihidrodiazpinocarbazolonas tetra o penta-cicliclas fusionadas como inhibidores de poli (adp-ribosa) polimerasa (parp).
IN2014CN02283A (lt)
IN2012DE02913A (lt)
UY34836A (es) Nuevo organismos
HK1213251A1 (zh) 作為突變 抑制劑的 -嘧啶- -基-噁唑烷- -酮化合物
CO7111289A2 (es) Compuestos inhibidores de metaloenzimas
IN2015DN00127A (lt)
UY33925A (es) Inhibidores tricíclicos de quinasas
CR20130539A (es) Triazolopiridinas
PH12013500500A1 (en) Fused heteroaryls and their uses
UY34158A (es) Composicion herbicida
HK1198365A1 (en) Imidazopyridine compounds, compositions and methods of use
UY34016A (es) Nuevo uso de aclidinio
IN2012DE02933A (lt)
UY34099A (es) ?composición de agentes de coalescencia?.
BR112015000468A2 (pt) composição detergente
UY34449A (es) Composicion de limpieza
UY33996A (es) Preparacion sólida
IN2011KO00551A (lt)
UA72478U (ru) Применение полентара как средства фригопротекторного действия
AU336924S (en) Hasp
TN2011000420A1 (fr) طريقة علمية لمقاومة التصحر وتخصيب الصحراء
IN2011KO01200A (lt)